BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, Hushmandi K, Hashemi M, Nabavi N, Crea F, Ren J, Klionsky DJ, Kumar AP, Wang Y. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res 2022;41:105. [PMID: 35317831 DOI: 10.1186/s13046-022-02293-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Mirzaei S, Paskeh MDA, Entezari M, Mirmazloomi SR, Hassanpoor A, Aboutalebi M, Rezaei S, Hejazi ES, Kakavand A, Heidari H, Salimimoghadam S, Taheriazam A, Hashemi M, Samarghandian S. SOX2 function in cancers: Association with growth, invasion, stemness and therapy response. Biomedicine & Pharmacotherapy 2022;156:113860. [DOI: 10.1016/j.biopha.2022.113860] [Reference Citation Analysis]
2 Hashemi M, Taheriazam A, Daneii P, Hassanpour A, kakavand A, Rezaei S, Hejazi ES, Aboutalebi M, Gholamrezaie H, Saebfar H, Salimimoghadam S, Mirzaei S, Entezari M, Samarghandian S. Targeting PI3K/Akt signaling in prostate cancer therapy. J Cell Commun Signal 2022. [DOI: 10.1007/s12079-022-00702-1] [Reference Citation Analysis]
3 Hashemi M, Mirdamadi MSA, Talebi Y, Khaniabad N, Banaei G, Daneii P, Gholami S, Ghorbani A, Tavakolpournegari A, Farsani ZM, Zarrabi A, Nabavi N, Zandieh MA, Rashidi M, Taheriazam A, Entezari M, Khan H. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106568] [Reference Citation Analysis]
4 Paskeh MDA, Ghadyani F, Hashemi M, Abbaspour A, Zabolian A, Javanshir S, Razzazan M, Mirzaei S, Entezari M, Goharrizi MASB, Salimimoghadam S, Aref AR, Kalbasi A, Rajabi R, Rashidi M, Taheriazam A, Sethi G. Biological function and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: promises and challenges. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106553] [Reference Citation Analysis]
5 Zandieh MA, Farahani MH, Rajabi R, avval ST, Karimi K, Rahmanian P, Razzazan M, Javanshir S, Mirzaei S, Paskeh MDA, Salimimoghadam S, Hushmandi K, Taheriazam A, Pandey V, Hashemi M. Epigenetic regulation of autophagy by non-coding RNAs in gastrointestinal tumors: Biological functions and therapeutic perspectives. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106582] [Reference Citation Analysis]
6 Mundekkad D, Cho WC. Mitophagy Induced by Metal Nanoparticles for Cancer Treatment. Pharmaceutics 2022;14:2275. [DOI: 10.3390/pharmaceutics14112275] [Reference Citation Analysis]
7 Gong T, Zheng C, Ou X, Zheng J, Yu J, Chen S, Duan Y, Liu W. Glutamine metabolism in cancers: Targeting the oxidative homeostasis. Front Oncol 2022;12:994672. [DOI: 10.3389/fonc.2022.994672] [Reference Citation Analysis]
8 Zhang Y, Lv W, Li H, Dong T, Wu H, Su C, Shu H, Nie F. Exploring the relationship between autophagy and Gefitinib resistance in NSCLC by silencing PDLIM5 using ultrasound-targeted microbubble destruction technology. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02718-4] [Reference Citation Analysis]
9 Hashemi M, Mirzaei S, Barati M, Hejazi ES, Kakavand A, Entezari M, Salimimoghadam S, Kalbasi A, Rashidi M, Taheriazam A, Sethi G. Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects. Life Sci 2022;309:120984. [PMID: 36150461 DOI: 10.1016/j.lfs.2022.120984] [Reference Citation Analysis]
10 Zhou X, Lin J, Wang F, Chen X, Zhang Y, Hu Z, Jin X. Circular RNA-regulated autophagy is involved in cancer progression. Front Cell Dev Biol 2022;10:961983. [DOI: 10.3389/fcell.2022.961983] [Reference Citation Analysis]
11 Chen CL, Lin YC. Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target. Int J Mol Sci 2022;23:10055. [PMID: 36077452 DOI: 10.3390/ijms231710055] [Reference Citation Analysis]
12 Ghasemii K, Darroudi M, Rahimmanesh I, Ghomi M, Hassanpour M, Sharifi E, Yousefiasl S, Ahmadi S, Zarrabi A, Borzacchiello A, Rabiee M, Paiva-santos AC, Rabiee N. Advances in aptamer-based drug delivery vehicles for cancer therapy. Biomaterials Advances 2022;140:213077. [DOI: 10.1016/j.bioadv.2022.213077] [Reference Citation Analysis]
13 Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M, Daneshi S, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions. Biomed Pharmacother 2022;154:113609. [PMID: 36037786 DOI: 10.1016/j.biopha.2022.113609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Duan L, Xia Y, Li C, Lan N, Hou X. Identification of Autophagy-Related LncRNA to Predict the Prognosis of Colorectal Cancer. Front Genet 2022;13:906900. [DOI: 10.3389/fgene.2022.906900] [Reference Citation Analysis]
15 Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res 2022;41:214. [PMID: 35773731 DOI: 10.1186/s13046-022-02406-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
16 Zhang Y, Xin Z, Dong B, Xue W, Huang T. Combination of the NRF2 Inhibitor and Autophagy Inhibitor Significantly Inhibited Tumorigenicity of Castration-Resistant Prostate Cancer. Computational and Mathematical Methods in Medicine 2022;2022:1-11. [DOI: 10.1155/2022/4182401] [Reference Citation Analysis]
17 Ashrafizadeh M, Zarrabi A, Karimi‐maleh H, Taheriazam A, Mirzaei S, Hashemi M, Hushmandi K, Makvandi P, Nazarzadeh Zare E, Sharifi E, Goel A, Wang L, Ren J, Nuri Ertas Y, Kumar AP, Wang Y, Rabiee N, Sethi G, Ma Z. (Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Arif A, Khawar MB, Mehmood R, Abbasi MH, Sheikh N. Dichotomous role of autophagy in cancer. Asian Biomedicine 2022;16:111-120. [DOI: 10.2478/abm-2022-0014] [Reference Citation Analysis]
19 Santana GL, Crovace MC, Mazón EE, de Oliveira AJA, Pavan TZ, Zanotto ED. Smart Bone Graft Composite for Cancer Therapy Using Magnetic Hyperthermia. Materials (Basel) 2022;15:3187. [PMID: 35591525 DOI: 10.3390/ma15093187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Sadrkhanloo M, Entezari M, Orouei S, Zabolian A, Mirzaie A, Maghsoudloo A, Raesi R, Asadi N, Hashemi M, Zarrabi A, Khan H, Mirzaei S, Samarghandian S. Targeting Nrf2 in ischemia-reperfusion alleviation: From signaling networks to therapeutic targeting. Life Sci 2022;:120561. [PMID: 35460707 DOI: 10.1016/j.lfs.2022.120561] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Iranmanesh H, Entezari M, Rejali L, Nazemalhosseini-mojarad E, Maghsoudloo M, Aghdaei HA, Zali MR, Hushmandi K, Rabiee N, Makvandi P, Ashrafizadeh M, Hashemi M. The Association of Clinicopathological Characterizations of Colorectal Cancer with Membrane-Bound Mucins genes and LncRNAs. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153883] [Reference Citation Analysis]